US4123384A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Control serum containing alkaline phosphatase of constant activity
Assignee: Roche Diagnostics GmbH
•
Filing: 1976-08-16
•
Granted: 1978-10-31
•
Expires: 1996-08-16
Abstract
Abstract The activity of alkaline phosphatase in aqueous solution, especially in reconstituted serum, is kept constant by adding to the phosphatase-containing solution Mn2+ or Cd2+ ions, preferably to an end concentration of 0.05 to 0.5 mMol/liter of Mn2+ or 0.05 to 0.1 mMol/liter of Cd2+. Control serums comprising the Mn2+ and/or Cd2+ ions in human or animal serum or serum-like compositions are also provided.
Inventors
- 👤 Dieter Hundt
- 👤 Wolfgang Gruber
- 👤 Michael Klarwein
- 👤 Peter Roeschlau
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:27
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/34; C12Q1/42; C12N; C12N9/00; C12N9/14; C12N9/16; C12N9/96; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/106664
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
55 words
Process for substantially stabilizing the activity of alkaline phosphatase in an aqueous control solution containing a predetermined amount of alkaline phosphatase which process comprises adding at least one of Mn 2+ and Cd 2+ ions to said solution, in an amount sufficient to substantially improve the stability of the activity of said alkaline phosphatase therein.
Claim 2
Dependent Claim
55 words
Process for substantially stabilizing the activity of alkaline phosphatase in an aqueous control solution containing a predetermined amount of alkaline phosphatase which process comprises adding at least one of Mn 2+ and Cd 2+ ions to said solution, in an amount sufficient to substantially improve the stability of the activity of said alkaline phosphatase therein.
Claim 3
Dependent Claim
15 words
Process as claimed in claim 1, wherein Mn 2+ ions are added to said solution.
Claim 4
Dependent Claim
15 words
Process as claimed in claim 1, wherein Cd 2+ ions are added to said solution.
Claim 5
Dependent Claim
21 words
Process as claimed in claim 1, wherein a mixture of Mn 2+ and Cd 2+ ions are added to said solution.
Claim 6
Dependent Claim
20 words
Process as claimed in claim 1, wherein Mn 2+ is added to an end concentration of 0.05 to 0.5 mMol/liter.
Claim 7
Dependent Claim
20 words
Process as claimed in claim 1, wherein Cd 2+ is added to an end concentration of 0.05 to 0.1 mMol/liter.
Claim 8
Dependent Claim
15 words
Process as claimed in claim 1, wherein the aqueous solution containing alkaline phosphatase is serum.
Claim 9
Dependent Claim
19 words
Process as claimed in claim 7, wherein Mn 2+ and/or Cd 2+ is added to the serum before lyophilization.
Claim 10
Dependent Claim
24 words
Process as claimed in claim 7, wherein Mn 2+ and/or Cd 2+ is added to the water used for the reconstitution of lyophilized serum.
Claim 11
Dependent Claim
50 words
Aqueous control solution having substantially stabilized alkaline phosphatase activity comprising a predetermined amount of alkaline phosphatase in an aqueous solution and at least one of Mn 2+ and Cd 2+ ions dissolved therein, in an amount sufficient to substantially improve the stability of the activity of said alkaline phosphatase therein.
Claim 12
Dependent Claim
50 words
Aqueous control solution having substantially stabilized alkaline phosphatase activity comprising a predetermined amount of alkaline phosphatase in an aqueous solution and at least one of Mn 2+ and Cd 2+ ions dissolved therein, in an amount sufficient to substantially improve the stability of the activity of said alkaline phosphatase therein.
Claim 13
Dependent Claim
34 words
Control serum comprising serum or serum substitute having a predetermined amount of alkaline phosphatase therein and containing from 0.05 to 0.5 mMol/liter of Mn 2+ and/or 0.05 to 0.1 mMol/liter of Cd 2+ .
Claim 14
Dependent Claim
34 words
Control serum comprising serum or serum substitute having a predetermined amount of alkaline phosphatase therein and containing from 0.05 to 0.5 mMol/liter of Mn 2+ and/or 0.05 to 0.1 mMol/liter of Cd 2+ .
Claim 15
Dependent Claim
13 words
Control serum as claimed in claim 11, wherein said serum is human serum.
Claim 16
Dependent Claim
13 words
Control serum as claimed in claim 11, wherein said serum is animal serum.
Claim 17
Dependent Claim
14 words
Control serum as claimed in claim 11, also comprising at least one additional enzyme.
Claim 18
Dependent Claim
8 words
Control composition as claimed in claim 11, comprising
Claim 19
Dependent Claim
40 words
1 to 5 mg creatinine, 0.1 to 5 mg bilirubin, 50 to 300 mg glucose, 0.3 to 3 mg Mn 2+ , and 0.6 to 1.2 mg Cd 2+ , and alkaline phosphatase in 100 ml serum or serum substitute.
Claim 20
Dependent Claim
40 words
1 to 5 mg creatinine, 0.1 to 5 mg bilirubin, 50 to 300 mg glucose, 0.3 to 3 mg Mn 2+ , and 0.6 to 1.2 mg Cd 2+ , and alkaline phosphatase in 100 ml serum or serum substitute.
Claim 21
Dependent Claim
52 words
Control serum as claimed in claim 11, comprising 0.5 to 1.5 mg creatinine, 0.5 to 1.5 mg bilirubin, 100 to 200 mg glucose, 1 to 3 mg manganese (II) chloride hydrate, acetic acid for the adjustment of the pH value of from 6.0 to 7.0, and alkaline phosphatase in 100 ml serum.
References Cited (Backward Citations)
US2999793A
Cited
US3466306A
Cited
US3425912A
Cited
US3595756A
Cited
US3723579A
Cited
US3728226A
Cited
US3926735A
Cited
US3876375A
Cited
US3876375B1
Cited
US3853465A
Cited
US3905872A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-10-30 | 1982-05-01 | 1982-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-10-30 | 1986-05-01 | 1986-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-10-30 | 1990-05-01 | 1990-10-31 | $7700.00 | Window Closed / Lapsed |